Navigation Links
Cepheid Announces Accelerated Development of Flu A Panel Test
Date:9/9/2009

applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market. See www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the timing of new product releases, the timing and likelihood of regulatory review and approval, product performance, and future market opportunities. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen product development and manufacturing problems; uncertainties in the regulatory review process for new products; regulatory developments and practices regarding testing; customer and market acceptance of the product; the failure of the product to perform as expected, whether due to manufacturing errors, design defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the product; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2008 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

    CONTACTS:
    F
'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Reports 2009 Second Quarter Results
3. Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection
4. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
5. Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference
6. Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test
7. Blue Mountain Quality Resources Announces that Cepheid has Selected Blue Mountain Regulatory Asset Manager
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Announces European Release of First On-Demand Molecular Pre-Surgical Screening Test for Simultaneous Detection of Methicillin-Sensitive and Resistant S. aureus
10. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 04, 2015 Los Angeles ... offering a more comfortable and attractive alternative for patients ... choice for those who have lost teeth. Unfortunately, they ... insecure or slip at the worst possible moment and ... talks. They can also painfully pinch or rub gums, ...
(Date:5/4/2015)... Chicago, Ill., (PRWEB) May 04, 2015 ... the American Brain Tumor Association (ABTA) show that people ... their diagnosis and treatment options, including clinical trials, at ... of days to make difficult decisions about their course ... the launch of the first nationwide brain tumor volunteer ...
(Date:5/4/2015)... San Diego Fertility Center (SDFC) ... new, 13,700 square foot facility scheduled to open in ... only provide fertility treatment and services for the center’s ... educational events to a number of local and international ... to their current Carmel Valley/Del Mar location and will ...
(Date:5/4/2015)... New West Medicare is excited to announce ... manage outpatient advanced imaging services for its members. Care ... members are provided the right test at the right ... New West Medicare’s physicians and hospitals, Care to Care ... imaging and provide an objective basis for informed evidence-based ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased to ... America’s Best Dentist Award, given by the National Consumer ... dentist is a reflection of his vast experience in ... for his patients. , Each year, the National Consumer ... field. These nominees are dentists who have exceptionally high ...
Breaking Medicine News(10 mins):Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2
... Goodwin HealthDay Reporter , MONDAY, Dec. 12 (HealthDay ... other children, a finding that researchers say may provide a ... see. Blinking is largely an involuntary process that helps ... that your eyes are closed, you are temporarily blinded. And ...
... US Prostate Cancer Prevention Trial found cancer in many men ... which PSA level should lead to a biopsy recommendation. ... considerable controversy, that the evidence does not support recommending PSA ... the risks outweigh the benefits. Now, a study shows ...
... News) -- ,Cancer patients receiving chemotherapy most often develop ... according to a large new study. Efforts to ... treatment should focus on outpatients -- not those still ... blood clot, also called a venous thromboembolism (VTE), is ...
... retrospective study shows that children of childhood cancer survivors ... ovaries and/or chemotherapy with alkylating agents do not have ... of survivors who did not have such cancer treatment. ... defects are unlikely for cancer survivors who are concerned ...
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- When she ... pound, Madeline Mann was the world,s smallest surviving baby. At ... of world,s tiniest infant, weighing in at 0.57 pounds. She was ... in the neonatal intensive care unit at Loyola University Medical Center ...
... , MONDAY, Dec. 12 (HealthDay News) -- The poet Emily ... that she "never met this fellow/Attended or alone/Without a tighter ... in her ophidiophobia (fear of snakes) and, it turns out, ... it is found in the grass or elsewhere. A ...
Cached Medicine News:Health News:Blink Patterns May Be a Window Into Autistic Mind 2Health News:Blink Patterns May Be a Window Into Autistic Mind 3Health News:Biopsy referral after PSA screening stays consistent over time 2Health News:Cancer Outpatients at Greater Risk for Blood Clots 2Health News:Childhood cancer survivors' exposure to chemotherapy, radiation does not increase risk of birth defects in their children 2Health News:Childhood cancer survivors' exposure to chemotherapy, radiation does not increase risk of birth defects in their children 3Health News:Childhood cancer survivors' exposure to chemotherapy, radiation does not increase risk of birth defects in their children 4Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 3Health News:Snakes Make Your Skin Crawl? Study Suggests Why 2
(Date:5/4/2015)... N.J. , May 4, 2015  Oncobiologics, ... commercializing monoclonal antibody (mAb) biosimilars, has completed the ... at its headquarters in Cranbury, New ... Cranbury facility is designed to utilize ... manufacturing at commercial scale.  Through the use of ...
(Date:5/4/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... the agreement, Isis is eligible to receive up to ... million up-front payment and a $55 million payment upon ... in patients with compromised kidney function. Isis is also ...
(Date:5/4/2015)... 2015  Geneia, a company of experienced healthcare ... improve healthcare efficiencies, today announced a first-of-its-kind partnership ... (BNRC) use Geneia,s advanced analytics solution coupled with ... and lower the cost of patient care. ... and utilization data from multiple sources to create ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
... Privigen®, the first and only ... proline, is effective and well tolerated in patients ... data presented today at the XIVth Meeting of ... that Privigen offers significant protection against ...
... CHAPEL HILL, N.C., Oct. 6 Pharmaceutical and biotech ... they ensure strong partnerships between R&D and marketing, balancing ... product development. It requires companies to break down the ... instead leverage the strengths of both talented medical researchers ...
Cached Medicine Technology:Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 2Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 3Creating Partnerships Across R&D and Marketing to Ensure a Successful Global Launch 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: